Evidence map›Paper›PMID 40305209›Full record

ArticleBiomolecules2025

Somatostatin Mitigates Gastric Mucosal Damage Induced by LPS in a Male Wistar Rat Model of Sepsis.

Sergio D Paredes, Jorge Hernández-Cortés, Farzin Falahat, Lisa Rancan, Javier Arias-Díaz, Elena Vara

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. International journal of molecular sciences · 2026
    Article
  3. From Glycocalyx Shedding to Microvascular Collapse in Sepsis: Endothelial Pathophysiology, Organ Dysfunction, and Mechanistic Biomarkers.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sergio D ParedesDepartment of Physiology, School of Medicine, Complutense University of Madrid, Avda. Complutense, s/n, 28040 Madrid, Spain.ORCID 0000-0002-4646-4199
Jorge Hernández-CortésDepartment of Biochemistry and Molecular Biology, School of Medicine, Complutense University of Madrid, Avda. Complutense, s/n, 28040 Madrid, Spain.
Farzin FalahatDepartment of Surgery, School of Medicine, Complutense University of Madrid, Avda. Complutense, s/n, 28040 Madrid, Spain.ORCID 0000-0002-6172-2993
Lisa RancanDepartment of Biochemistry and Molecular Biology, School of Medicine, Complutense University of Madrid, Avda. Complutense, s/n, 28040 Madrid, Spain.ORCID 0000-0003-1556-192X
Javier Arias-DíazDepartment of Surgery, School of Medicine, Complutense University of Madrid, Avda. Complutense, s/n, 28040 Madrid, Spain.ORCID 0000-0002-3002-3305
Elena VaraDepartment of Biochemistry and Molecular Biology, School of Medicine, Complutense University of Madrid, Avda. Complutense, s/n, 28040 Madrid, Spain.ORCID 0000-0002-5361-5215

Funding

Ayuda del Plan Regional de Investigación de la Comunidad de Madrid 08.1/0013.1Proyecto Investigación Complutense PR1/03
6 · The paper itself

Abstract

Upper gastrointestinal bleeding from erosive gastritis remains associated with high mortality in septic or postoperative patients. While stress ulcer bleeding has declined, it still occurs in septic patients and is considered a manifestation of intestinal failure within multi-organ failure syndrome. The integrity of the gastric mucosal barrier plays a crucial role in protection against this condition. Somatostatin (SS) appears as a biomolecule with cytoprotective properties. We aimed to investigate whether SS treatment protected the gastric mucosa in a rat model of lipopolysaccharide (LPS)-induced sepsis. Rats received LPS (10 mg/kg) intraperitoneally, followed by saline or SS (200 μg/kg; 5 mL/kg) treatment after 30 min (early treatment group) or 120 min (late treatment group). Control rats received only saline. Two hours after saline or SS administration (total procedure duration of 150 or 240 min), gastric lavage, gastric mucosa, and plasma samples were collected for analysis. SS treatment mitigated the LPS-induced gastric mucosal barrier disruption preserving phosphatidylcholine (PC) levels, as well as decreasing leukocyte infiltration marker myeloperoxidase (MPO), inflammation-related enzyme phospholipase A2 (PLA2), and lipid peroxidation indicator malondialdehyde (MDA). SS also reduced arachidonic acid-related metabolites thromboxane B2 (TXB2) and leukotriene B4 (LTB4) while increasing prostaglandin I2 (PGI2). SS treatment effectively maintained gastric mucosal integrity, reducing inflammation, and modulating arachidonic acid metabolites. These findings suggest that SS may serve as a therapeutic agent for preserving gastric mucosal integrity and reducing inflammation in LPS-induced gastric injury.

Indexed as

Gastric MucosaLipopolysaccharidesSepsisSomatostatinAnimalsDisease Models, AnimalLipid PeroxidationMalePeroxidaseRatsRats, WistarThromboxane B2LipopolysaccharidesPeroxidaseSomatostatinThromboxane B2gastric mucosaleukotriene B4LPS-induced sepsismalondialdehydemyeloperoxidasephosphatidylcholinephospholipase A2prostaglandin I2somatostatinthromboxane B2

Identifiers

PMID40305209
PMCPMC12025147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.